Bristol-Myers Squibb Co news

   Watch this stock
Showing stories 1 - 10 of about 167   

Articles published

BMY 64.65 +0.35 (0.54%)
price chart
Bristol-Myers Squibb Company (NYSE:BMY) Had Its Price Objective Upped by ...
In a note shared with investors by Leerink Swann on Tuesday, 28 July, Bristol-Myers Squibb Company (NYSE:BMY) had its target price per share boosted to $77.00.
Active Stocks News Alert: General Electric Company (NYSE:GE), Bristol-Myers ...  wsnewspublishers
Large Inflow of Money Witnessed in Bristol-Myers Squibb Company  American Trade Journal
Bristol-Myers Squibb Co. (BMY) Falls 2.55% for July 27
One of the S&P 500's big losers for Monday July 27 was Bristol-Myers Squibb Co. (BMY). The company's stock fell 2.55% to $64.30 on volume of 9.23 million shares.
Bristol-Myers Squibb Posts Upbeat Q2 Results, Lifts Profit Forecast
Bristol-Myers Squibb Co (NYSE: BMY) reported stronger-than-expected earnings for the second quarter and raised its profit forecast for the full year.
Bristol-Myers Squibb Company (BMY) Leading In Pre-Market Activity  TheStreet.com
Bristol-Myers' hepatitis C drug sales eclipsed expectations  Business Insider
Analyst's Key Takeaways From Eli Lilly, Bristol-Myer Squibb's Latest ...
In separate reports published Thursday, Evercore-ISI's Biotechnology analyst Mark Schoenebaum dissected Eli Lilly and Co (NYSE: LLY) and Bristol-Myers Squibb Co (NYSE: BMY)'s conference call following the release of their quarterly results.
Did McDonald's, Caterpillar & Amazon Lose Sizzle To Strong Dollar?
Also on the docket to release earnings ahead of Thursday's trading day are Bristol-Myers Squibb Co (NYSE: BMY) and Eli Lilly And Co (NYSE: LLY).
Bristol-Myers Squibb Co. (BMY) Falls 3.31% for July 24
One of the S&P 500's big losers for Friday July 24 was Bristol-Myers Squibb Co. (BMY). The company's stock fell 3.31% to $65.98 on volume of 6.81 million shares.
Bristol-Myers' HIV-1 Drug Approved In Europe
Shares of Bristol-Myers Squibb Co (NYSE: BMY) were boosted higher on Thursday after the company announced the European Commission approved its Evotaz for the treatment of HIV-1 in adults.
Bristol-Myers Squibb Co HIV-1 Combo Approved In Europe; A Win For Gilead ...  Bidness ETC
Company Update (NYSE:BMY): European Commission Approves Bristol-Myers Squibb ...  Jutia Group
Stock to Follow: Bristol-Myers Squibb Co (NYSE:BMY)
[Business Wire] Bristol-Myers Squibb Co (NYSE:BMY)(TREND ANALYSIS) announced that the European Commission has approved Nivolumab BMS for the treatment of locally advanced or metastatic squamous (SQ) non-small cell lung cancer (NSCLC) after ...
European Commission Approves Nivolumab BMS by Bristol-Myers Squibb for NSCLC  Lung Disease News
Earnings Whispers: Bristol-Myers Squibb Co, Celgene Corporation & Valeant ...
Bristol-Myers Squibb Co. (NYSE:BMY), Celgene Corporation (NASDAQ:CELG), and Valeant Pharmaceuticals Intl Inc. (NYSE:VRX) are all scheduled to release their financial results for the quarter ended June 30, 2015, in pre-market hours today.
Bristol-Myers Squibb Company (BMY) Highlighted As Momo Momentum Stock
In addition to specific proprietary factors, Trade-Ideas identified Bristol-Myers Squibb Company as such a stock due to the following factors: BMY has an average dollar-volume (as measured by average daily share volume multiplied by share price) of ...